Pasithea Therapeutics
KTTA
21 hedge funds and large institutions have $9.52M invested in Pasithea Therapeutics in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
2.19% less ownership
Funds ownership: 57.71% → 55.51% (-2.2%)
19% less funds holding
Funds holding: 26 → 21 (-5)
43% less capital invested
Capital invested by funds: $16.7M → $9.52M (-$7.17M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCC
Cable Car Capital
San Francisco,
California
|
+$591K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$465K |
| 3 |
Renaissance Technologies
New York
|
+$78.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.4K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$27.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$581K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$484K |
| 3 |
SC
Stempoint Capital
New York
|
-$458K |
| 4 |
Jane Street
New York
|
-$76.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$72.5K |
KTTA Hedge Fund Activity: Q1 2026 in Review
21 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q1 2026, worth a combined $9.52M — down 43% from $16.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of KTTA and 3 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Cable Car Capital, adding an estimated $591K. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $581K sold.
- 21 institutional investors held Pasithea Therapeutics (KTTA) as of Q1 2026, down from 26 in Q4 2025.
- Funds reported $9.52M of Pasithea Therapeutics stock for Q1 2026, down 43% quarter-over-quarter.
- 3 funds opened new Pasithea Therapeutics positions in Q1 2026 and 7 closed out, a net change of -4 holders.
- The largest Pasithea Therapeutics buyer in Q1 2026 was Cable Car Capital, an estimated $591K added.
- The largest Pasithea Therapeutics seller in Q1 2026 was Acuta Capital Partners, an estimated $581K sold.
Based on aggregated 13F filings for Q1 2026.